Q3 2025 Mirum Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Mirum Pharmaceuticals Inc (MIRM) reported a strong commercial performance with third quarter revenue of $133 million, marking a nearly 50% year-over-year increase.
- The company achieved positive net income for the first time, highlighting the operating leverage in their commercial model.
- Mirum Pharmaceuticals Inc (MIRM) is on track for three potentially pivotal readouts over the next 18 months, including the VISTAS Phase 2b study in PSC.
- The company has a robust pipeline with ongoing studies such as the VANTAGE study of volixibat in PDC and the EXPAND study of LIVMARLI in ultra-rare cholestatic conditions.
- Mirum Pharmaceuticals Inc (MIRM) has strengthened its financial foundation with a significant increase in cash balance, reaching $378 million by the end of the third quarter.
- The company faces variability in international sales, particularly with LIVMARLI, due to periodic large orders from distributors.
- There is uncertainty regarding the appropriate pricing strategy for volixibat, as the company is still analyzing market dynamics.
- Mirum Pharmaceuticals Inc (MIRM) anticipates potential Paragraph four filers, which could challenge their intellectual property portfolio.
- The company acknowledges the need for sustained engagement and education in genetic testing, particularly among adult-focused providers.
- Mirum Pharmaceuticals Inc (MIRM) does not expect additional sales to their partner Takeda in Japan for the fourth quarter, which may impact revenue.
Hello, and welcome to the Mirum Pharmaceuticals third quarter 2025 financial results and business update. My name is Harry, and I'll be your operator today. (Operator Instructions)
I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.
Thanks, Harry, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals third quarter 2025 conference call. I'm joined today by our CEO, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; a Chief Medical Officer, Joanne M. Quan; and Eric Bjerkholt, our Chief Financial Officer.
Earlier today, Mirum issued a news release announcing the company's results for the third quarter of 2025. Copies of this news release and SEC filings can be found in the Investors section of our website.
Before we start, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements based
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
